ZymoGenetics, Inc: Pharmaceuticals and Healthcare Company Profile & SWOT Report

iCD Research
February 6, 2012
15 Pages - SKU: ICDR6793329
License type:
Table of Contents Search inside this report Related Reports
Synopsis

ICD Research's ZymoGenetics, Inc: Pharmaceuticals and Healthcare Company Profile & SWOT Report contains in depth information and data about the company and its operations. The profile contains a company overview, business description, SWOT analysis, key facts, information on products and services, plus information on key news events affecting the company.

Summary

ICD Research's ZymoGenetics, Inc: Pharmaceuticals and Healthcare Company Profile & SWOT Report is a crucial resource for industry executives and anyone looking to access key information about ZymoGenetics, Inc..

ICD Research's ZymoGenetics, Inc: Pharmaceuticals and Healthcare Company Profile & SWOT Report report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Scope
  • Examines and identifies key information and issues about ZymoGenetics, Inc. for business intelligence requirements.
  • Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
  • The profile also contains information on business operations, company history, major products and services, prospects, key employees.
Reasons To Buy
  • Quickly enhance your understanding of ZymoGenetics, Inc. .
  • Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
  • Increase business/sales activities by understanding your competitors’ businesses better.
  • Recognize potential partnerships and suppliers.
Key Highlights

ZymoGenetics, Inc. (ZymoGenetics) is a biotechnology company, which develops and markets therapeutic proteins for the treatment of human diseases. The company's development programs are principally focused on hemostasis, cancer, viral infections, inflammatory and autoimmune diseases. ZymoGenetics portfolio of products comprised of a commercial product, RECOTHROM Thrombin, topical (Recombinant) and three immunology product candidates: PEG-IFN-lambda, IL-21, and IL-31 mAb. Furthemore, its out-licensed product candidates comprise of Atacicept, Augment, rFactor XIII, FGF-18, IL-17RC, IL-20, IL-22RA and IL-21 mAb. After its acquisition by Bristol-Myers Squibb Company (BMC) in October 2011, it functions as a wholly owned subsidiary of BMC. The company is headquartered in Seattle, Washington, the US.


 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!